IPO News Archive
Seattle-based biotech Omeros prices IPO at $10.00, at low end of the range

10/8/09


Omeros, which is developing drugs for the treatment of surgery-related inflammation and pain, raised $68 million by offering 6.82 million shares at $10, at low end of the proposed $10 to $12 range. Shares are expected to begin trading Thursday on the NASDAQ under the symbol OMER. Deutsche Bank was lead manager on the deal.

View IPO Profile: OMER         
Source: www.RenaissanceCapital.com
Latest User Comments

Attribution Policy: The information contained herein is proprietary and copyrighted. The media is welcome to use our information and ideas, provided that the following sourcing is included: Renaissance Capital, Greenwich, CT (www.renaissancecapital.com).
Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital and/or the IPO Plus Fund (symbol: IPOSX) may have investments in securities of companies mentioned.
Invest in the IPO Plus Fund
About Fund Prospectus Invest